XPOVIO (Page 6 of 6)

14.2 Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The efficacy of XPOVIO monotherapy was evaluated in SADAL (KCP-330-009; NCT02227251). SADAL was a multicenter, single-arm, open-label study of adults with relapsed or refractory DLBCL, not otherwise specified (NOS), after 2 to 5 systemic regimens. Eligible patients were not candidates for autologous hematopoietic stem cell transplantation (HSCT). The study required a minimum of 60 days since last systemic therapy, with a minimum of 98 days in patients with refractory disease (defined as less than partial response) to last systemic therapy.

Patients received XPOVIO 60 mg orally on Days 1 and 3 of each week. Treatment continued until disease progression or unacceptable toxicity.

Of 134 patients evaluated, the median age was 67 years (range: 35-91), 59% were male, 79% were White, and 7% were Asian. Most patients (88%) had an ECOG performance status of 0 or 1. The diagnosis was de novo DLBCL not otherwise specified (NOS) in 75% and transformed DLBCL in 23%. The median number of prior systemic therapies was 2 (range: 1-5), with 63% of patients receiving 2 prior systemic therapies, 24% receiving 3 prior therapies, and 10% receiving 4 or 5 prior therapies. Twenty-eight percent had documented refractory disease to the most recent therapy; 30% had prior autologous HSCT. The median time from last systemic therapy to the start of XPOVIO was 5.4 months overall and 3.6 months in the patients with refractory disease.

Efficacy was based on overall response rate (ORR) and duration of response as assessed by an Independent Review Committee (IRC) using Lugano 2014 criteria (Table 12). The median time to first response was 8.1 weeks (range: 6.7-16.4 weeks).

Table 12: Efficacy Results per IRC in Relapsed or Refractory DLBCL (SADAL)
Parameter XPOVIO 60 mg twice weekly (n=134)
ORR per Lugano criteria, n (%) 95% CI, % 39 (29)22, 38
Complete Response 18 (13)
Partial Response 21 (16)
Duration of Response
Patients maintaining response at 3 months, n/N (%) 22/39 (56)
Patients maintaining response at 6 months, n/N (%) 15/39 (38)
Patients maintaining response at 12 months, n/N (%) 6/39 (15)

16 HOW SUPPLIED/STORAGE AND HANDLING

XPOVIO (selinexor) are blue, round, bi-convex, and film-coated 20 mg tablets with “K20” debossed on one side and nothing on the other side. Tablets are packaged in a child-resistant blister pack. Four blister packs are supplied per carton. The following seven dose presentations are available:

Weekly dose Strength per tablet Carton Blister Pack NDC
80 mg twice weekly 20 mg 4 blister packs (32 tablets total in the carton) Each blister has eight 20 mg tablets Outer carton NDC 72237-101-04Blister pack NDC 72237-101-14
60 mg twice weekly 20 mg 4 blister packs (24 tablets total in the carton) Each blister has six 20 mg tablets Outer carton NDC 72237-101-03Blister pack NDC 72237-101-13
100 mg once weekly 20 mg 4 blister packs (20 tablets total in the carton) Each blister has five 20 mg tablets Outer carton NDC 72237-101-05Blister pack NDC 72237-101-15
80 mg once weekly 20 mg 4 blister packs (16 tablets total in the carton) Each blister has four 20 mg tablets Outer carton NDC 72237-101-02Blister pack NDC 72237-101-12
40 mg twice weekly 20 mg 4 blister packs (16 tablets total in the carton) Each blister has four 20 mg tablets Outer carton NDC 72237-101-06Blister pack NDC 72237-101-16
60 mg once weekly 20 mg 4 blister packs (12 tablets total in the carton) Each blister has three 20 mg tablets Outer carton NDC 72237-101-01Blister pack NDC 72237-101-11
40 mg once weekly 20 mg 4 blister packs (8 tablets total in the carton) Each blister has two 20 mg tablets Outer carton NDC 72237-101-07Blister pack NDC 72237-101-17

Store at or below 30°C (86°F).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Dosing Instructions [see Dosage and Administration (2)]:

  • Instruct patients to take XPOVIO exactly as prescribed.
  • Advise patients to swallow the tablet whole with water. The tablet should not be broken, chewed, crushed, or divided.
  • If a patient misses a dose, advise them to take their next dose at its regularly scheduled time. If a patient vomits or misses a dose of XPOVIO, advise them to take the next dose on the next regularly scheduled day.
  • Advise patients that XPOVIO comes in a child-resistant blister pack.
  • Advise patients to take their prescribed dexamethasone (if applicable) and prophylactic anti-nausea medications as directed [see Dosage and Administration (2.1, 2.3)].
  • Advise patients that blood tests and body weight will be monitored at baseline and during treatment as clinically indicated, with more frequent monitoring during the first three months of treatment [see Dosage and Administration (2.3)].
  • Advise patients to maintain appropriate fluid and caloric intake throughout their treatment [see Dosage and Administration (2.4)].

Hematologic Adverse Reactions

Thrombocytopenia

Advise patients that they may develop low platelet counts (thrombocytopenia). Symptoms of thrombocytopenia may include bleeding and easy bruising. Advise patients that platelet counts will be monitored at baseline, during treatment, and as clinically indicated, with more frequent monitoring during the first 3 months of treatment. Advise patients to report signs of bleeding right away [see Warnings and Precautions (5.1)].

Anemia

Advise patients that they may develop anemia. Symptoms of anemia may include fatigue and shortness of breath. Advise patients to report signs or symptoms of anemia [see Adverse Reactions (6.1)].

Neutropenia

Advise patients that they may develop low neutrophil counts which may increase their susceptibility to infection [see Warnings and Precautions (5.2)]. Advise patients that neutrophil counts will be monitored at baseline, during treatment, and as clinically indicated, with more frequent monitoring during the first 3 months of treatment.

Gastrointestinal Adverse Reactions

Advise patients they may experience nausea/vomiting or diarrhea and to contact their physician if these adverse reactions occur or persist [see Warnings and Precautions (5.3)].

Advise patients that they may experience weight loss or decreased appetite. Advise patients to report decreased appetite and weight loss [see Warnings and Precautions (5.3)].

Hyponatremia

Advise patients that they may develop low sodium levels (hyponatremia). Most cases of hyponatremia were not associated with specific symptoms. Advise patients that levels of sodium will be monitored at baseline and during treatment as clinically indicated, with more frequent monitoring during the first two months of treatment [see Warnings and Precautions (5.4)].

Serious Infection

Advise patients of the possibility of serious infections. Instruct patients to immediately report infection-related signs or symptoms (e.g., chills, fever) [see Warnings and Precautions ( 5.5)].

Neurotoxicity

Advise patients that they may experience confusion and dizziness. Advise patients to report symptoms of neurological toxicity right away. Advise patients not to drive or operate hazardous machinery until the neurological toxicity fully resolves. Advise patients to use fall prevention measures as warranted [see Warnings and Precautions ( 5.6)].

Embryo-Fetal Toxicity

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to contact their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.7) and Use in Specific Populations ( 8.1)].

Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the final dose [see Use in Specific Populations ( 8.3)].

Fatigue

Advise patients that they may experience fatigue [see Adverse Reactions (6.1)].

Lactation

Advise women not to breastfeed during treatment with XPOVIO and for 1 week after the final dose [see Use in Specific Populations ( 8.2)].

Concomitant Medications

Advise patients to take 5-HT3 antagonist prophylactic treatment and other anti-nausea agents prior to and during treatment with XPOVIO [see Dosage and Administration ( 2.4)].

Advise patients to speak with their physician about other medications they are currently taking and before starting any new medication.

Manufactured for and marketed by: Karyopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA, 02459.

XPOVIO is a registered trademark of Karyopharm Therapeutics Inc.

©2020 Karyopharm Therapeutics Inc.

For more information, call 1-888-209-9326 or go to www.XPOVIO.com.

This Medication Guide has been approved by the U.S. Food and Drug Administration

Revised: June 2020

MEDICATION GUIDE XPOVIO® (x-PO-Vee-O)(selinexor)tablets

What is the most important information I should know about XPOVIO? XPOVIO can cause serious side effects, including:

  • Low platelet counts. Low platelet counts are common with XPOVIO and can lead to bleeding which can be severe and can sometimes cause death. Your healthcare provider may prescribe platelet transfusions or other treatments for your low platelet counts.Tell your healthcare provider right away if you have any bleeding or easy bruising during treatment with XPOVIO.
  • Low white blood cell counts. Low white blood cell counts are common with XPOVIO and can sometimes be severe. You may have an increased risk of getting bacterial infections during treatment with XPOVIO. Your healthcare provider may prescribe antibiotics if you have signs or symptoms of infection, or certain medicines to help increase your white blood cell count, if needed.
Your healthcare provider will do blood tests before you start taking XPOVIO, and often during the first 3 months of treatment, and then as needed during treatment to monitor you for side effects.Your healthcare provider may change your dose of XPOVIO, stop your treatment for a period of time, or completely stop your treatment if you have certain side effects during treatment with XPOVIO.See “What are the possible side effects of XPOVIO?” for more information about side effects.
What is XPOVIO? XPOVIO is a prescription medicine used:
  • in combination with dexamethasone to treat adults with multiple myeloma (MM) that has come back (relapsed) or that did not respond to previous treatment (refractory), and
    • who have received at least 4 prior therapies, and
    • whose disease did not respond to (refractory) to at least 2 proteasome inhibitor medicines, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody medicine.
  • to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who have received at least 2 prior therapies
It is not known if XPOVIO is safe and effective in children less than 18 years of age.
What should I tell my healthcare provider before taking XPOVIO? Before taking XPOVIO, tell your healthcare provider about all of your medical conditions, including if you:
  • have or have had a recent or active infection
  • have or have had bleeding problems
  • are pregnant or plan to become pregnant. XPOVIO can harm your unborn baby.Females who are able to become pregnant:
    • Your healthcare provider will check to see if you are pregnant before you start taking XPOVIO.
    • You should use effective birth control (contraception) during treatment with XPOVIO and for 1 week after your last dose.
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with XPOVIO.
    Males with female partners who are able to become pregnant:
    • You should use effective birth control during treatment with XPOVIO and for 1 week after your last dose.
  • are breastfeeding or plan to breastfeed. It is not known if XPOVIO passes into your breast milk.
    • Do not breastfeed during treatment with XPOVIO and for 1 week after your last dose of XPOVIO.
Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Talk with your healthcare provider before taking any new medicines.

How should I take XPOVIO?

  • Take XPOVIO exactly as prescribed by your healthcare provider.
  • If you have multiple myeloma, your healthcare provider will prescribe dexamethasone with your XPOVIO treatment. Take dexamethasone exactly as prescribed.
  • Your healthcare provider will tell you how much XPOVIO to take and when to take it. Do not change your dose or stop taking XPOVIO without talking to your healthcare provider first.
  • Swallow XPOVIO tablets whole with water. Do not break, chew, crush, or divide the tablets.
  • Be sure to take any medicines prescribed by your healthcare provider before and during treatment with XPOVIO to help prevent nausea and vomiting. Tell your healthcare provider if the prescribed medicine does not control your nausea and vomiting.
  • It is important for you to drink enough fluids to help prevent dehydration and to eat enough calories to help prevent weight loss during treatment with XPOVIO. Talk to your healthcare provider if this is a problem for you. See “What are the possible side effects of XPOVIO?
  • If you miss a dose of XPOVIO, take your next dose at your next regularly scheduled day and time.
  • If you vomit after taking a dose of XPOVIO, do not take an extra dose. Take your next dose at your next regularly scheduled day and time.
  • If you take too much XPOVIO, call your healthcare provider right away.
What should I avoid while taking XPOVIO? XPOVIO can cause neurologic side effects.
  • See “What are the possible side effects of XPOVIO?” below.
  • If you have any neurologic side effects with XPOVIO, do not drive or operate heavy or dangerous machinery until your neurologic side effects go away.
  • Avoid falling. Use care as needed to avoid falling due to neurologic side effects.

What are the possible side effects of XPOVIO? XPOVIO can cause serious side effects, including:

  • See “What is the most important information I should know about XPOVIO?
  • Nausea and vomiting. Nausea and vomiting are common with XPOVIO and can sometimes be severe. Nausea and vomiting may affect your ability to eat and drink well. You can lose too much body fluid and body salts (electrolytes) and may be at risk for becoming dehydrated. You may need to receive intravenous (IV) fluids or other treatments to help prevent dehydration. Your healthcare provider will prescribe anti-nausea medicines for you to take before you start and during treatment with XPOVIO. See “How should I take XPOVIO?
  • Diarrhea. Diarrhea is common with XPOVIO and can sometimes be severe. You can lose too much body fluid and body salts (electrolytes) and may be at risk for becoming dehydrated. You may need to receive IV fluids or other treatments to help prevent dehydration. Your healthcare provider will prescribe anti-diarrhea medicine for you as needed.
  • Loss of appetite and weight loss. Loss of appetite and weight loss are common with XPOVIO and can sometimes be severe. Tell your healthcare provider if you have a decrease or loss of appetite and if you notice that you are losing weight. Your healthcare provider may prescribe medicines that can help increase your appetite or prescribe other kinds of nutritional support.
  • Decreased sodium levels in your blood. Decreased sodium levels in your blood is common with XPOVIO but can also sometimes be severe. Low sodium levels in your blood can happen if you have nausea, vomiting, or diarrhea, you become dehydrated, or if you have loss of appetite with XPOVIO. You may not have any symptoms of a low sodium level. Your healthcare provider may talk with you about your diet and prescribe IV fluids for you based on the sodium levels in your blood. Your healthcare provider will do blood tests before you start taking XPOVIO, and often during the first 2 months of treatment, and then as needed during treatment to monitor the sodium levels in your blood.
  • Serious infections. Infections are common with XPOVIO and can be serious and can sometimes cause death. XPOVIO can cause infections including upper or lower respiratory tract infections, such as pneumonia, and an infection throughout your body (sepsis). Tell your healthcare provider right away if you have any signs or symptoms of an infection such as cough, chills or fever, during treatment with XPOVIO.
  • Neurologic side effects. XPOVIO can cause neurologic side effects that can sometimes be severe and life-threatening.
    • XPOVIO can cause dizziness, fainting, decreased alertness, and changes in your mental status including confusion and decreased awareness of things around you (delirium).
    • In some people, XPOVIO may also cause problems with thinking (cognitive problems), seeing or hearing things that are not really there (hallucinations), and may become very sleepy or drowsy.
    Tell your healthcare provider right away if you get any of these signs or symptoms.
Your healthcare provider may change your dose of XPOVIO, stop your treatment for a period of time, or completely stop your treatment if you have certain side effects during treatment with XPOVIO.
Common side effects of XPOVIO include:
  • tiredness
  • low red blood cell count (anemia). Symptoms may include tiredness and shortness of breath.
  • constipation
  • shortness of breath
  • increased blood sugar
  • changes in body salt and mineral levels in your blood
  • changes in kidney and liver function blood tests
XPOVIO may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.These are not all the possible side effects of XPOVIO.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store XPOVIO?
  • Store XPOVIO at or below 86°F (30°C).
  • XPOVIO comes in a child-resistant blister pack.
Keep XPOVIO and all medicines out of the reach of children.
General information about the safe and effective use of XPOVIO. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XPOVIO for a condition for which it was not prescribed. Do not give XPOVIO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about XPOVIO that is written for health professionals.
What are the ingredients in XPOVIO? Active ingredient: selinexorInactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, Opadry 200 clear, Opadry II blue, povidone K30, and sodium lauryl sulfate.Manufactured for and marketed by: Karyopharm Therapeutics Inc., 85 Wells Avenue, Newton, MA, 02459XPOVIO is a registered trademark of Karyopharm Therapeutics Inc.©2020 Karyopharm Therapeutics Inc.For more information, call 1-888-209-9326 or go to www.XPOVIO.com

Principal Display Panel – 60 mg (Once Weekly) Carton Label

NDC 72237-101-01

Rx ONLY

60 mg
Once
Weekly
Blister Packs

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 3 tablets (20 mg per tablet).

12 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 60 mg (Once Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 60 mg (Once Weekly) Blister Sleeve Label

NDC 72237-101-11

Rx ONLY

1 PRESS
& HOLD
HERE

60 mg
Once
Weekly
Blister Pack

1. PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
3 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,
or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 60 mg (Once Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 60 mg (Once Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

60 mg Dose (entire pack)

Push tablets through foil.

Swallow whole with water.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 60 mg dose in a single day per week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 60 mg (Once Weekly) Blister Pack Label
(click image for full-size original)

Principal Display Panel – 80 mg (Once Weekly) Carton Label

NDC 72237-101-02

Rx ONLY

80 mg
Once
Weekly
Blister Packs

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 4 tablets (20 mg per tablet).

16 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 80 mg (Once Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 80 mg (Once Weekly) Blister Sleeve Label

NDC 72237-101-12

Rx ONLY

1 PRESS
& HOLD
HERE

80 mg
Once
Weekly
Blister Pack

1. PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
4 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,
or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 80 mg (Once Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 80 mg (Once Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

80 mg
Dose
(entire pack)

Push tablets
through foil.

Swallow
whole withwater.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 80 mg dose in a single day per week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 80 mg (Once Weekly) Blister Pack Label
(click image for full-size original)

Principal Display Panel – 60 mg (Twice Weekly) Carton Label

NDC 72237-101-03

Rx ONLY

60 mg
Twice
Weekly
Blister Packs

(120 mg total weekly dose)

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 6 tablets (20 mg per tablet).

24 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 60 mg (Twice Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 60 mg (Twice Weekly) Blister Sleeve Label

NDC 72237-101-13

Rx ONLY

1 PRESS
& HOLD
HERE

60 mg
Twice
Weekly
Blister Pack

(120 mg total weekly dose)

1. PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
6 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,

or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 60 mg (Twice Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 60 mg (Twice Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

60 mg
Dose
(entire pack)

Push tablets
through foil.

Swallow
whole withwater.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 60 mg dose in a single day. Take one 60 mg dose on Day 1 and one 60 mg dose on Day 3 of the week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 60 mg (Twice Weekly) Blister Pack Label
(click image for full-size original)

Principal Display Panel – 80 mg (Twice Weekly) Carton Label

NDC 72237-101-04

Rx ONLY

80 mg
Twice
Weekly
Blister Packs

(160 mg total weekly dose)

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 8 tablets (20 mg per tablet).

32 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 80 mg (Twice Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 80 mg (Twice Weekly) Blister Sleeve Label

NDC 72237-101-14

Rx ONLY

1 PRESS
& HOLD
HERE

80 mg
Twice
Weekly
Blister Pack

(160 mg total weekly dose)

1.PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
8 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,
or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 80 mg (Twice Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 80 mg (twice Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

80 mg
Dose
(entire pack)

Push tablets
through foil.

Swallow
whole withwater.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 80 mg dose in a single day. Take one 80 mg dose on Day 1 and one 80 mg dose on Day 3 of the week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 80 mg (twice Weekly) Blister Pack Label
(click image for full-size original)

Principal Display Panel – 100 mg (Once Weekly) Carton Label

NDC 72237-101-05

Rx ONLY

100 mg
Once
Weekly
Blister Packs

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 5 tablets (20 mg per tablet).

20 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 100 mg (Once Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 100 mg (Once Weekly) Blister Sleeve Label

NDC 72237-101-15

Rx ONLY

1 PRESS
& HOLD
HERE

100 mg
Once
Weekly
Blister Pack

1.PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
5 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,

or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 100 mg (Once Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 100 mg (Once Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

100 mg
Dose
(entire pack)

Push tablets
through foil.

Swallow
whole withwater.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 100 mg dose in a single day per week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 100 mg (Once Weekly) Blister Pack Label
(click image for full-size original)

Principal Display Panel – 40 mg (Twice Weekly) Carton Label

NDC 72237-101-06

Rx ONLY

40 mg
Twice
Weekly
Blister Packs

(80 mg total weekly dose)

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 4 tablets (20 mg per tablet).

16 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 40 mg (Twice Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 40 mg (Twice Weekly) Blister Sleeve Label

NDC 72237-101-16

Rx ONLY

1 PRESS
& HOLD
HERE

40 mg
Twice
Weekly
Blister Pack

(80 mg total weekly dose)

1. PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
4 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,
or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 40 mg (Twice Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 40 mg (Twice Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

40 mg
Dose
(entire pack)

Push tablets
through foil.

Swallow
whole withwater.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 40 mg dose in a single day. Take one 40 mg dose on Day 1 and one 40 mg dose on Day 3 of the week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 40 mg (Twice Weekly) Blister Pack Label
(click image for full-size original)

Principal Display Panel – 40 mg (Once Weekly) Carton Label

NDC 72237-101-07

Rx ONLY

40 mg
Once
Weekly
Blister Packs

XPOVIO®

(selinexor) tablets

Contents: 4 individual weekly
blister packs. Each blister pack
contains 2 tablets (20 mg per tablet).

8 film-coated tablets

Dispense enclosed Medication Guide
to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 40 mg (Once Weekly) Carton Label
(click image for full-size original)

Principal Display Panel – 40 mg (Once Weekly) Blister Sleeve Label

NDC 72237-101-17

Rx ONLY

1 PRESS
& HOLD
HERE

40 mg
Once
Weekly
Blister Pack

1. PRESS 2. PULL

XPO VIO®

(selinexor) tablets

TO OPEN

Step 1: Press and
hold button gently.

Step 2: Pull out
medication card.

Blister pack contains
2 tablets (20 mg per tablet).

Refer to Prescribing
Information for dosing
instructions.

Do not break, chew, crush,
or divide the tablets.

Dispense enclosed Medication
Guide to each patient.

Karyopharm® Therapeutics

Principal Display Panel – 40 mg (Once Weekly) Blister Sleeve Label
(click image for full-size original)

Principal Display Panel – 40 mg (Once Weekly) Blister Pack Label

XPO VIO® (selinexor tablets)

40 mg Dose (entire pack)

Push tablets through foil.

Swallow whole with water.

IMPORTANT: Take each dose as prescribed by your physician.

Take only one 40 mg dose in a single day per week.

Refer to Prescribing Information for dosing instructions.

Principal Display Panel – 40 mg (Once Weekly) Blister Pack Label
(click image for full-size original)
XPOVIO selinexor tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:72237-101
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
selinexor (selinexor) selinexor 20 mg
Inactive Ingredients
Ingredient Name Strength
Microcrystalline Cellulose 101
Microcrystalline Cellulose 102
Croscarmellose Sodium
Povidone K30
Sodium Lauryl Sulfate
Silicon Dioxide
Magnesium Stearate
TALC
POLYVINYL ALCOHOL, UNSPECIFIED
GLYCERYL MONOSTEARATE
POLYSORBATE 80
TITANIUM DIOXIDE
POLYETHYLENE GLYCOL 3350
FD&C BLUE NO. 2–ALUMINUM LAKE
FD&C BLUE NO. 1 ALUMINUM LAKE
Product Characteristics
Color blue (blue) Score no score
Shape ROUND (ROUND) Size 7mm
Flavor Imprint Code K20
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:72237-101-04 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-14)
1 NDC:72237-101-14 8 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-04)
2 NDC:72237-101-05 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-15)
2 NDC:72237-101-15 5 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-05)
3 NDC:72237-101-02 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-12)
3 NDC:72237-101-12 4 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-02)
4 NDC:72237-101-01 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-11)
4 NDC:72237-101-11 3 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-01)
5 NDC:72237-101-03 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-13)
5 NDC:72237-101-13 6 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-03)
6 NDC:72237-101-06 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-16)
6 NDC:72237-101-16 4 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-06)
7 NDC:72237-101-07 4 BLISTER PACK in 1 CARTON contains a BLISTER PACK (72237-101-17)
7 NDC:72237-101-17 2 TABLET, FILM COATED in 1 BLISTER PACK This package is contained within the CARTON (72237-101-07)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA212306 07/10/2019
Labeler — Karyopharm Therapeutics Inc. (061317680)
Establishment
Name Address ID/FEI Operations
Carton Service, Incorporated 928861723 LABEL (72237-101), PACK (72237-101), RELABEL (72237-101)
Establishment
Name Address ID/FEI Operations
Catalent CTS, LLC 962674474 MANUFACTURE (72237-101)
Establishment
Name Address ID/FEI Operations
Integrated Commercialization Solutions, LLC 038187093 RELABEL (72237-101)
Establishment
Name Address ID/FEI Operations
Integrated Commercialization Solutions, LLC 832820588 RELABEL (72237-101)

Revised: 06/2020 Karyopharm Therapeutics Inc.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.